Zymeworks Raises $100M Via Equity Issued At 14% Discount

Zymeworks Inc ZYME has priced its underwritten public offering of 9.16 million common shares, pre-funded warrants to purchase up to 3.34 million shares. 

  • The shares are offered at $8.00 per common share and the pre-funded warrants at $7.9999 per pre-funded warrant. 
  • The offer price represents a discount of almost 14% from the last close price of $9.32 on Wednesday.
  • See the offer prospectus here.
  • The gross proceeds to Zymeworks are expected to be approximately $100.0 million. 
  • Underwriters have an option to purchase up to an additional 1.875 million shares.
  • The Company will use the proceeds to develop zanidatamab, adaptive Phase 1 trials of ZW49, and for general corporate purposes.
  • Related: Zymeworks To Cut Its Workforce By Almost 25%, Outlines 2022 & 2023 Priorities.
  • The offering is expected to close by January 31.
  • Price Action: ZYME shares are down 11.5% at $8.25 during the premarket session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareFinancingOfferingsSmall CapMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!